Prevention and treatment of pneumocystis carinii pneumonia

Walter T. Hughes

Research output: Contribution to journalArticle

Abstract

Several drugs are now available for the treatment and prevention of Pneumocystis carinii pneumonia. These include trimethoprim-sulfamethoxazole and pentamidine isethionate as first-line drugs and dapsone-trimethoprim, trimetrexate, piritrexim, fansidar, difluoromethylornithine, and clindamycin plus primaquine as drugs in later stages of clinical development. A hydroxynaphthoquinone, called 566C80, offers promise in preclinical studies. The use of corticosteroids in the supportive management of P. carinii pneumonitis is undergoing clinical study.

Original languageEnglish (US)
Pages (from-to)287-295
Number of pages9
JournalAnnual Review of Medicine
Volume42
StatePublished - 1991
Externally publishedYes

Fingerprint

Pneumocystis Pneumonia
Trimetrexate
Atovaquone
Pharmaceutical Preparations
Primaquine
Eflornithine
Pentamidine
Pneumocystis carinii
Dapsone
Trimethoprim
Clindamycin
Sulfamethoxazole Drug Combination Trimethoprim
Pneumonia
Adrenal Cortex Hormones

Keywords

  • Immunocompromised host
  • Pentamidine
  • Trimethoprim-sulfamethoxazole

ASJC Scopus subject areas

  • Cell Biology
  • Medicine(all)

Cite this

Prevention and treatment of pneumocystis carinii pneumonia. / Hughes, Walter T.

In: Annual Review of Medicine, Vol. 42, 1991, p. 287-295.

Research output: Contribution to journalArticle

Hughes, Walter T. / Prevention and treatment of pneumocystis carinii pneumonia. In: Annual Review of Medicine. 1991 ; Vol. 42. pp. 287-295.
@article{39853cf8173e47cf931dadc1dedad949,
title = "Prevention and treatment of pneumocystis carinii pneumonia",
abstract = "Several drugs are now available for the treatment and prevention of Pneumocystis carinii pneumonia. These include trimethoprim-sulfamethoxazole and pentamidine isethionate as first-line drugs and dapsone-trimethoprim, trimetrexate, piritrexim, fansidar, difluoromethylornithine, and clindamycin plus primaquine as drugs in later stages of clinical development. A hydroxynaphthoquinone, called 566C80, offers promise in preclinical studies. The use of corticosteroids in the supportive management of P. carinii pneumonitis is undergoing clinical study.",
keywords = "Immunocompromised host, Pentamidine, Trimethoprim-sulfamethoxazole",
author = "Hughes, {Walter T.}",
year = "1991",
language = "English (US)",
volume = "42",
pages = "287--295",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Prevention and treatment of pneumocystis carinii pneumonia

AU - Hughes, Walter T.

PY - 1991

Y1 - 1991

N2 - Several drugs are now available for the treatment and prevention of Pneumocystis carinii pneumonia. These include trimethoprim-sulfamethoxazole and pentamidine isethionate as first-line drugs and dapsone-trimethoprim, trimetrexate, piritrexim, fansidar, difluoromethylornithine, and clindamycin plus primaquine as drugs in later stages of clinical development. A hydroxynaphthoquinone, called 566C80, offers promise in preclinical studies. The use of corticosteroids in the supportive management of P. carinii pneumonitis is undergoing clinical study.

AB - Several drugs are now available for the treatment and prevention of Pneumocystis carinii pneumonia. These include trimethoprim-sulfamethoxazole and pentamidine isethionate as first-line drugs and dapsone-trimethoprim, trimetrexate, piritrexim, fansidar, difluoromethylornithine, and clindamycin plus primaquine as drugs in later stages of clinical development. A hydroxynaphthoquinone, called 566C80, offers promise in preclinical studies. The use of corticosteroids in the supportive management of P. carinii pneumonitis is undergoing clinical study.

KW - Immunocompromised host

KW - Pentamidine

KW - Trimethoprim-sulfamethoxazole

UR - http://www.scopus.com/inward/record.url?scp=0025865365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025865365&partnerID=8YFLogxK

M3 - Article

C2 - 2035974

AN - SCOPUS:0025865365

VL - 42

SP - 287

EP - 295

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -